Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 166
Filter
1.
Dig Dis Sci ; 69(8): 3069-3078, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38824258

ABSTRACT

BACKGROUND: In many Asian hepatocellular carcinoma (HCC) guidelines, resection is an option for multiple HCCs. It is difficult to compare small but multiple tumors vs. fewer large tumors in terms of the traditional tumor burden definition. We aimed to evaluate the role of liver resection for multiple HCCs and determine factors associated with survival benefits. METHODS: We reviewed 160 patients with multiple HCCs who underwent liver resection between July 2003 and December 2018. The risk factors for tumor recurrence were assessed using Cox proportional hazards modeling, and survival was analyzed using the Kaplan-Meier method. RESULTS: In all 160 patients, 133 (83.1%) exceeded the Milan criteria. Total tumor volume (TTV) > 275 cm3 and serum alpha-fetoprotein (AFP) level > 20 ng/mL were associated with disease-free survival. Patients beyond the Milan criteria were grouped into three risk categories: no risk (TTV ≤ 275 cm3 and AFP ≤ 20 ng/mL, n = 39), one risk (either TTV > 275 cm3 or AFP > 20 ng/mL, n = 76), and two risks (TTV > 275 cm3 and AFP > 20 ng/mL, n = 18). No-risk group had comparable disease-free survival (p = 0.269) and overall survival (p = 0.215) to patients who met the Milan criteria. CONCLUSION: Patients with TTV ≤ 275 cm3 and AFP ≤ 20 ng/mL can have good outcomes even exceed the Milan criteria.


Subject(s)
Carcinoma, Hepatocellular , Hepatectomy , Liver Neoplasms , Tumor Burden , Humans , Carcinoma, Hepatocellular/surgery , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/blood , Liver Neoplasms/surgery , Liver Neoplasms/pathology , Liver Neoplasms/mortality , Liver Neoplasms/blood , Male , Female , Middle Aged , Hepatectomy/methods , Aged , Retrospective Studies , alpha-Fetoproteins/metabolism , alpha-Fetoproteins/analysis , Risk Factors , Neoplasm Recurrence, Local/epidemiology , Disease-Free Survival , Neoplasms, Multiple Primary/surgery , Neoplasms, Multiple Primary/pathology , Neoplasms, Multiple Primary/blood , Neoplasms, Multiple Primary/mortality , Adult
3.
Am J Surg ; 222(3): 483-489, 2021 09.
Article in English | MEDLINE | ID: mdl-33551118

ABSTRACT

BACKGROUND: Primary hyperparathyroidism (PHPT) caused by double adenoma may carry a higher risk of failure to cure. We compared outcomes in single adenoma (SA), double adenoma (DA) and four-gland hyperplasia (HP). METHODS: Patients undergoing initial parathyroidectomy for PHPT were categorized by diagnosis. The primary outcome was persistent/recurrent disease postoperatively. RESULTS: Of 3408 patients, 81.3% had SA, 9.5% had DA, and 9.3% had HP. Rates of persistence/recurrence were 2.9%, 5.3%, and 4.5% in SA, DA, and HP, respectively (p = 0.281). Patients with persistence/recurrence had higher preoperative calcium (11.0 vs 10.7 mg/dl, p = 0.028) and PTH (96 vs 77 pg/ml, p = 0.015), and lower rates of IOPTH normalization (77% vs 96%, p < 0.001). On multivariable analysis, DA was associated with increased risk of persistent/recurrent disease (OR 3.0, p = 0.017). CONCLUSIONS: Most patients with DA are cured with removal of two glands, but approximately 5% experience disease persistence/recurrence. Low-normal final IOPTH was associated with lower risk of persistent/recurrent disease.


Subject(s)
Adenoma/complications , Hyperparathyroidism, Primary/etiology , Neoplasms, Multiple Primary/complications , Parathyroid Glands/pathology , Parathyroid Neoplasms/complications , Adenoma/blood , Adenoma/pathology , Adenoma/surgery , Aged , Calcium/blood , Female , Humans , Hypercalcemia/etiology , Hyperparathyroidism, Primary/blood , Hyperparathyroidism, Primary/epidemiology , Hyperparathyroidism, Primary/surgery , Hyperplasia/blood , Hyperplasia/epidemiology , Hyperplasia/pathology , Intraoperative Period , Male , Middle Aged , Multivariate Analysis , Neoplasm Recurrence, Local/blood , Neoplasm Recurrence, Local/epidemiology , Neoplasms, Multiple Primary/blood , Neoplasms, Multiple Primary/pathology , Neoplasms, Multiple Primary/surgery , Parathyroid Glands/surgery , Parathyroid Hormone/blood , Parathyroid Neoplasms/blood , Parathyroid Neoplasms/pathology , Parathyroid Neoplasms/surgery , Parathyroidectomy , Preoperative Period , Recurrence , Retrospective Studies , Risk , Treatment Outcome
4.
World J Urol ; 39(7): 2567-2577, 2021 Jul.
Article in English | MEDLINE | ID: mdl-33067726

ABSTRACT

PURPOSE: The accurate selection of patients who are most likely to benefit from neoadjuvant chemotherapy is an important challenge in oncology. Serum AGR has been found to be associated with oncological outcomes in various malignancies. We assessed the association of pre-therapy serum albumin-to-globulin ratio (AGR) with pathologic response and oncological outcomes in patients treated with neoadjuvant platin-based chemotherapy followed by radical nephroureterectomy (RNU) for clinically non-metastatic UTUC. METHODS: We retrospectively included all clinically non-metastatic patients from a multicentric database who had neoadjuvant platin-based chemotherapy and RNU for UTUC. After assessing the pretreatment AGR cut-off value, we found 1.42 to have the maximum Youden index value. The overall population was therefore divided into two AGR groups using this cut-off (low, < 1.42 vs high, ≥ 1.42). A logistic regression was performed to measure the association with pathologic response after NAC. Univariable and multivariable Cox regression analyses tested the association of AGR with OS and RFS. RESULTS: Of 172 patients, 58 (34%) patients had an AGR < 1.42. Median follow-up was 26 (IQR 11-56) months. In logistic regression, low AGR was not associated with pathologic response. On univariable analyses, pre-therapy serum AGR was neither associated with OS HR 1.15 (95% CI 0.77-1.74; p = 0.47) nor RFS HR 1.48 (95% CI 0.98-1.22; p = 0.06). These results remained true regardless of the response to NAC. CONCLUSION: Pre-therapy low serum AGR before NAC followed by RNU for clinically high-risk UTUC was not associated with pathological response or long-term oncological outcomes. Biomarkers that can complement clinical factors in UTUC are needed as clinical staging and risk stratification are still suboptimal leading to both over and under treatment despite the availability of effective therapies.


Subject(s)
Carcinoma, Transitional Cell/blood , Carcinoma, Transitional Cell/therapy , Globulins/analysis , Kidney Neoplasms/blood , Kidney Neoplasms/therapy , Neoplasms, Multiple Primary/blood , Neoplasms, Multiple Primary/therapy , Nephroureterectomy , Serum Albumin/analysis , Ureteral Neoplasms/blood , Ureteral Neoplasms/therapy , Aged , Humans , Middle Aged , Neoadjuvant Therapy , Retrospective Studies , Treatment Outcome
5.
Medicine (Baltimore) ; 99(44): e22904, 2020 Oct 30.
Article in English | MEDLINE | ID: mdl-33126344

ABSTRACT

This study was to investigate clinical features and prognosis of duplex primary malignant neoplasms involving chronic myeloid leukemia (CML-DPMNs). Clinical data of thirteen CML-DPMN patients who were admitted to the First Hospital of Jilin University from May 2008 to December 2018 were collected and retrospectively analyzed. Female patients (9/13) were predominant in this cohort study. Nine patients were metachronous DPMNs (metachronous duplex primary malignant neoplasms involving chronic myeloid leukemia) with 5 years median interval time from primary malignancy to secondary malignancy. The other 4 patients were diagnosed as synchronous CML-DPMNs. Seven of the metachronous duplex primary malignant neoplasms involving chronic myeloid leukemia suffered from CML following many years of comprehensive anti-cancer therapy. Two of CML-MDPMN patients had invasive ductal carcinoma of breast after many years of treatment with imatinib. There was no difference between treatment-related CML group and non-treatment-related CML group in regard as the gender, age, white blood cell count, hemoglobin level, platelet count, and risk level. The median overall survival time of these thirteen patients with CML-DPMNs was not reached. In conclusion, female patients are more likely to suffer from the CML-DPMNs in the present article. Overall survival time of patients with DPMNs involving CML could be promising if timely and effective treatment therapy is adopted.


Subject(s)
Breast Neoplasms , Imatinib Mesylate/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Neoplasms, Multiple Primary , Age Factors , Anticarcinogenic Agents/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , China/epidemiology , Female , Humans , Incidence , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/epidemiology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Male , Middle Aged , Neoplasms, Multiple Primary/blood , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/epidemiology , Neoplasms, Multiple Primary/pathology , Prognosis , Retrospective Studies , Risk Factors , Sex Factors , Survival Analysis , Time Factors
8.
BMC Endocr Disord ; 20(1): 63, 2020 May 11.
Article in English | MEDLINE | ID: mdl-32393372

ABSTRACT

BACKGROUND: Prediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several obesity-related adipocytokines, is an independent influencing factor for colonic polyps in prediabetes subjects. However, the correlation between adipocytokine levels and colonic polyps in prediabetes subjects is unclear. This research explores the relationship between plasma adiponectin, visfatin, leptin, and resistin levels and the development of colonic polyps in prediabetes subjects. METHODS: A total of 468 prediabetes subjects who underwent electronic colonoscopy examinations were enrolled in this study; there were 248 cases of colonic polyps and 220 cases without colonic mucosal lesions. Then, colonic polyps patients with prediabetes were subdivided into a single-polyp group, multiple-polyps group, low-risk polyps group, or high-risk polyps group. In addition, 108 subjects with normal glucose tolerance who were frequency matched with prediabetes subjects by sex and age were selected as the control group; 46 control subjects had polyps, and 62 control subjects were polyp-free. Plasma adiponectin, visfatin, leptin, and resistin levels were measured in all the subjects, and the related risk factors of colonic polyps in prediabetes subjects were analysed. RESULTS: Plasma adiponectin levels were significantly lower in the polyps group than in the polyp-free group [normal glucose tolerance (9.8 ± 4.8 vs 13.3 ± 3.9) mg/L, P = 0.013; prediabetes (5.6 ± 3.7 vs 9.2 ± 4.4) mg/L, P = 0.007]. In prediabetes subjects, plasma adiponectin levels were decreased significantly in the multiple polyps group [(4.3 ± 2.6 vs 6.7 ± 3.9) mg/L, P = 0.031] and the high-risk polyps group [(3.7 ± 2.9 vs 7.4 ± 3.5) mg/L, P < 0.001] compared to their control groups. Plasma visfatin levels were higher in the polyps group and the multiple-polyps group than those in their control groups (P = 0.041 and 0.042, respectively), and no significant difference in plasma leptin and resistin levels was observed between these three pairs of groups (all P > 0.05). The multivariate logistic regression analysis showed that lower levels of plasma adiponectin was a risk factor for colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. CONCLUSIONS: Plasma adiponectin levels are inversely associated with colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. And adiponectin may be involved in the development of colon tumours in prediabetes subjects.


Subject(s)
Adenomatous Polyps/blood , Adiponectin/blood , Colonic Polyps/blood , Colorectal Neoplasms/blood , Cytokines/blood , Leptin/blood , Nicotinamide Phosphoribosyltransferase/blood , Prediabetic State/blood , Resistin/blood , Adenomatous Polyps/pathology , Adult , Aged , Case-Control Studies , China/epidemiology , Colonic Polyps/pathology , Colonoscopy , Colorectal Neoplasms/epidemiology , Colorectal Neoplasms/pathology , Female , Humans , Male , Middle Aged , Neoplasms, Multiple Primary/blood , Neoplasms, Multiple Primary/pathology , Prediabetic State/epidemiology , Risk Factors
9.
Urology ; 140: 155-158, 2020 06.
Article in English | MEDLINE | ID: mdl-32199873

ABSTRACT

Bilateral testicular tumors are very rare in pediatric patients and only a few case reports have been reported. These patients have a high risk of sterility due to bilateral orchiectomy and subsequent gonadotoxic treatments. Therefore, if possible, testis-sparing surgery should be performed in patients with benign masses and testicular tissue preservation may be recommended in order to maintain fertility in later life. We present a 23 months old boy with synchronous bilateral testicular tumor managed with unilateral orchiectomy and testis-sparing surgery and testicular tissue cryopreservation performed to the controlateral side. We also review the literature on bilateral testis tumors in children.


Subject(s)
Cryopreservation/methods , Neoplasms, Germ Cell and Embryonal , Neoplasms, Multiple Primary , Orchiectomy/methods , Organ Sparing Treatments/methods , Teratoma , Testicular Neoplasms , Testis , Humans , Infant , Male , Neoplasms, Germ Cell and Embryonal/blood , Neoplasms, Germ Cell and Embryonal/pathology , Neoplasms, Germ Cell and Embryonal/surgery , Neoplasms, Multiple Primary/blood , Neoplasms, Multiple Primary/pathology , Neoplasms, Multiple Primary/surgery , Teratoma/blood , Teratoma/pathology , Teratoma/surgery , Testicular Neoplasms/blood , Testicular Neoplasms/pathology , Testicular Neoplasms/surgery , Testis/diagnostic imaging , Testis/pathology , Testis/surgery , Tissue Preservation/methods , Treatment Outcome , Ultrasonography/methods , alpha-Fetoproteins/analysis
10.
Article in English | MEDLINE | ID: mdl-31074463

ABSTRACT

BACKGROUND: The roles of sphingosine in various cancers have not been fully investigated. Our aim was to identify the relationship between serum sphingosine and the risk of hepatocellular carcinoma (HCC). METHODS: Serum sphingosine in 34 normal people and 73 HCC patients were reviewed retrospectively. Receiver operating characteristic curve analysis was performed to determine the cut-off values of sphingosine in the serum. Chi-square test, t test and regression analysis were used to test the association between serum sphingosine and individual clinicopathologic parameters. RESULTS: Serum sphingosine was higher in HCC patients (155.91±331.5 ng/mL) with normal persons as the control (30.92±29.4 ng/mL). The sphingosine threshold according to ROC curve was set at 22.5 ng/mL with a sensitivity of 74%, and a specificity of 55.9%. Meanwhile, sphingosine in HCC patients with abnormal albumin was significantly higher than that in patients with normal albumin (t=2.452, P=0.019). When HCC patients were divided into two groups serum sphingosine was negatively associated with albumin in HCC patients (χ2=4.469, P=0.035). Moreover, the logistic regression analysis showed that large tumor size (P=0.018, OR=0.13) and a low albumin (P=0.005, OR=8.856) were two independent risk factors for serum sphingosine upregulation. High AFP coupled with high serum sphingosine, high sphingosine and high AFP respectively were found in 91.2%, 75.4%, 73% of the HCC patients. CONCLUSIONS: These results suggest that serum sphingosine could be treated as a marker for the risk of HCC. AFP and sphingosine in the serum could be used together for HCC diagnosis.


Subject(s)
Carcinoma, Hepatocellular/blood , Liver Neoplasms/blood , Neoplasms, Multiple Primary/blood , Serum Albumin/metabolism , Sphingosine/blood , Carcinoma, Hepatocellular/complications , Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/pathology , Case-Control Studies , Female , Humans , Liver Cirrhosis/blood , Liver Cirrhosis/complications , Liver Neoplasms/complications , Liver Neoplasms/diagnosis , Liver Neoplasms/pathology , Male , Middle Aged , Neoplasms, Multiple Primary/complications , Neoplasms, Multiple Primary/diagnosis , ROC Curve , Risk , Tumor Burden , alpha-Fetoproteins/metabolism
11.
Hormones (Athens) ; 18(3): 273-279, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31332766

ABSTRACT

PURPOSE: To evaluate a single-center extensive experience and effectiveness in surgical treatment of primary hyperparathyroidism (pHPT) with the use of rapid intraoperative parathyroid hormone (ioPTH) monitoring in patients with single gland (SGpH) or multiple gland (MGpH) disease. METHODS: This retrospective, single-center cohort study included 214 patients with pHPT treated from January 2010 to June 2017. In total, 172 patients fulfilled the inclusion criteria having at least one preoperative localization image study and measurement of ioPTH. Statistical analysis was made by the chi-square test and Student's t tests. RESULTS: Of the 172 patients, 146 were women (85%) and 26 men (15%), with a mean age of 56.9 years; 153 (89%) had SGpH and 19 (11%) MGpH. The mean follow-up was 41.8 months. A total of 153 surgical procedures were performed as minimal invasive parathyroidectomy (MIP) based on a SGpH diagnosis; operative success was achieved in 150 cases (98%), according to ioPTH concentrations. The remainder (19 procedures) were performed as bilateral neck exploration (BNE) based on a MGpH diagnosis; operative success was achieved in 16 cases (84%). ioPTH correctly modified the initially planned operation in 26.3% of patients with MGpH. CONCLUSIONS: ioPTH enables the surgical treatment of patients with pHPT with focused approaches and excellent results, as it helps the surgeon to identify cases of MGpH. ioPTH adds value to cases where preoperative imaging failed to detect the affected gland or the results are inconclusive. According to the literature, its application seems to be of marginal benefit in cases in which there are two concordant preoperative imaging studies.


Subject(s)
Adenoma/surgery , Hyperparathyroidism, Primary/surgery , Monitoring, Intraoperative/methods , Neoplasms, Multiple Primary/surgery , Parathyroid Hormone/blood , Parathyroid Neoplasms/surgery , Adenoma/blood , Adolescent , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Follow-Up Studies , Humans , Hyperparathyroidism, Primary/blood , Hyperparathyroidism, Primary/diagnosis , Male , Middle Aged , Neoplasms, Multiple Primary/blood , Parathyroid Hormone/analysis , Parathyroid Neoplasms/blood , Parathyroidectomy/methods , Retrospective Studies , Young Adult
12.
Colorectal Dis ; 21(4): 432-440, 2019 04.
Article in English | MEDLINE | ID: mdl-30578740

ABSTRACT

AIM: Whether some diseases are related to the occurrence of synchronous colorectal carcinoma (sCRC) is unknown. Investigating the risk factors and presentation of sCRC could aid in the treatment of patients with colorectal cancer (CRC). The prognosis of sCRC compared with that of solitary CRC remains unclear. METHODS: A total of 17 093 CRC patients were recruited between 1st January 1995 and 31th December 2016. The risk factors of sCRC development were assessed using univariate and multivariate logistic regression. The effect of sCRC on survival was analysed using the multivariate Cox regression model. RESULTS: The prevalence of sCRC was 5.6% in this study. The independent risk factors of sCRC development were advanced age (P < 0.001), male sex (P < 0.001), hereditary cancer (P < 0.001), hypertension (P < 0.001) and liver cirrhosis (P = 0.024). Compared with solitary CRC, a higher number of patients with sCRC presented with an abnormal carcinoembryonic antigen (CEA) level (P = 0.011), anaemia (P < 0.001) and hypoalbuminemia (P < 0.001). Multivariate analysis revealed that sCRC was a significant factor for poor survival in patients at TNM Stage I [hazard ratio (HR) = 1.86; P < 0.001], Stage II (HR = 1.65; P < 0.001) and Stage III (HR = 1.40; P < 0.001). CONCLUSIONS: In addition to hypertension and liver cirrhosis, other risk factors for sCRC were identified in this study. The prognosis of patients with sCRC was significantly worse than that of those with solitary CRC through TNM Stages I to III. Anaemia, abnormal CEA and hypoalbuminemia were more commonly seen in patients with sCRC.


Subject(s)
Carcinoma/mortality , Colorectal Neoplasms/mortality , Neoplasms, Multiple Primary/mortality , Aged , Biomarkers, Tumor/blood , Carcinoembryonic Antigen/blood , Carcinoma/pathology , Colorectal Neoplasms/blood , Colorectal Neoplasms/pathology , Female , Humans , Logistic Models , Male , Middle Aged , Neoplasm Staging , Neoplasms, Multiple Primary/blood , Neoplasms, Multiple Primary/pathology , Prognosis , Proportional Hazards Models , Prospective Studies , Retrospective Studies , Risk Factors , Survival Rate
13.
HPB (Oxford) ; 21(1): 107-113, 2019 01.
Article in English | MEDLINE | ID: mdl-30017783

ABSTRACT

BACKGROUND: To investigate the clinical value of the alpha-fetoprotein (AFP) response following transcatheter arterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma (HCC). METHODS: Data on patients with Barcelona Clinic Liver Cancer B staging system were analyzed. An AFP response was defined as a decrease in AFP of more than 20% after a TACE session. The association between AFP response and treatment outcome regarding imaging response and overall survival (OS) was explored. Cox proportional hazards models were applied to identify independent risk factors for OS after TACE. RESULTS: Of the enrolled 376 patients with elevated serum AFP >20 ng/mL, 214 (57%) with AFP responses were identified. AFP responders had improved median survival than non-responders (20 vs. 12 months, P = 0.002). AFP response was significantly correlated with imaging response (P < 0.001). The Cox proportional hazards model revealed that AFP response was an independent factor for OS (hazard ratio, 0.59; 95% confidence interval, 0.45-0.78; P < 0.001). In stratified analyses, an AFP response achieved improved survival in patients with tumor diameters ≤5 cm, diameters >5 cm, tumor number ≤3 and without underlying cirrhosis. CONCLUSIONS: The AFP response indicates enhanced survival after TACE in patients with intermediate-stage BCLC.


Subject(s)
Carcinoma, Hepatocellular/therapy , Chemoembolization, Therapeutic , Liver Neoplasms/therapy , Neoplasms, Multiple Primary/therapy , alpha-Fetoproteins/metabolism , Adult , Aged , Aged, 80 and over , Carcinoma, Hepatocellular/blood , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/pathology , Chemoembolization, Therapeutic/adverse effects , Chemoembolization, Therapeutic/mortality , Female , Humans , Liver Neoplasms/blood , Liver Neoplasms/mortality , Liver Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Neoplasms, Multiple Primary/blood , Neoplasms, Multiple Primary/mortality , Neoplasms, Multiple Primary/pathology , Retrospective Studies , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome , Tumor Burden
14.
Can J Gastroenterol Hepatol ; 2018: 3120185, 2018.
Article in English | MEDLINE | ID: mdl-30009156

ABSTRACT

Macroscopic portal vein invasion (PVT) by hepatocellular carcinoma (HCC) in the liver is one of the most important negative prognostic factors for HCC patients. The characteristics of a large cohort of such patients were examined. We found that the percent of patients with PVT significantly increased with increasing maximum tumor diameter (MTD), from 13.7% with tumors of MTD <5cm to 56.4% with tumors of MTD >10cm. There were similar numbers of HCC patients with very large tumors with and without PVT. Thus, MTD alone was insufficient to explain the presence of PVT, as were high AFP levels, since less than 50% of high AFP patients had PVT. However, the percent of patients with PVT was also found to significantly increase with increasing blood alpha-fetoprotein (AFP) levels and tumor multifocality. A logistic regression model that included these 3 factors together showed an odds ratio of 17.9 for the combination of MTD>5.0cm plus tumor multifocality plus elevated AFP, compared to low levels of these 3 parameters. The presence or absence of macroscopic PVT may therefore represent different HCC aggressiveness phenotypes, as judged by a significant increase in tumor multifocality and AFP levels in the PVT positive patients. Factors in addition to MTD and AFP must also contribute to PVT development.


Subject(s)
Carcinoma, Hepatocellular/pathology , Liver Neoplasms/pathology , Neoplasms, Multiple Primary/pathology , Neoplastic Cells, Circulating , Portal Vein/pathology , Venous Thrombosis/etiology , Aged , Carcinoma, Hepatocellular/blood , Carcinoma, Hepatocellular/complications , Female , Humans , Liver Neoplasms/blood , Liver Neoplasms/complications , Male , Middle Aged , Neoplasm Invasiveness , Neoplasms, Multiple Primary/blood , Neoplasms, Multiple Primary/complications , Tumor Burden , alpha-Fetoproteins/metabolism
16.
Curr Probl Cancer ; 41(6): 413-418, 2017.
Article in English | MEDLINE | ID: mdl-29129340

ABSTRACT

Multiple primary malignant neoplasms (MPMNs) are rare malignant neoplasms that simultaneously or successively occur in the same patient as 2 or more primary malignancies. Currently, an increasing number of cases are being reported. In general, MPMNs more commonly occur as 2 solid tumors or 2 hematological malignancies. Cases of MPMN that involve a solid tumor and a hematological malignancy are rare. Here, we report a case of synchronous colorectal cancer (CRC) and multiple myeloma (MM) with chest wall involvement. After reviewing the literature, we believe that there may be a distinct syndrome involving CRC and MM. The patient in our case study suffered refractory anemia following surgery and 2 cycles of chemotherapy. Initially, the anemia was considered to be a common manifestation of CRC in this patient. Interestingly, although he received a blood transfusion, his hemoglobin levels remained low. He later developed hematuria, proteinuria, multiple osteoporosis in the costal bones, and thrombocytopenia. These new symptoms drew our attention, and we considered a diagnosis of synchronous primary CRC and MM, with the anemia as a symptom of MM. Based on the results of a bone marrow aspirate, MM was confirmed. Therefore, when CRC is associated with refractory anemia, we should not only assume that anemia is a classical symptom of CRC, a result of chronic blood loss, nutritional deficiencies, or myelosuppression due to chemotherapy, but we should also consider that it may reflect the possibility of a coexisting hematologic malignancy. As the treatment of these 2 malignancies is different, early diagnosis and treatment based on definitive diagnosis as early as possible will be beneficial to overall prognosis.


Subject(s)
Adenocarcinoma/therapy , Anemia, Refractory/therapy , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Colorectal Neoplasms/therapy , Multiple Myeloma/therapy , Neoplasms, Multiple Primary/therapy , Adenocarcinoma/blood , Adenocarcinoma/diagnosis , Adenocarcinoma/pathology , Anemia, Refractory/blood , Anemia, Refractory/diagnosis , Anemia, Refractory/etiology , Biopsy , Chemotherapy, Adjuvant/adverse effects , Colectomy , Colonoscopy , Colorectal Neoplasms/blood , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/pathology , Early Detection of Cancer , Fluorouracil/adverse effects , Humans , Leucovorin/adverse effects , Male , Middle Aged , Multiple Myeloma/blood , Multiple Myeloma/diagnosis , Multiple Myeloma/pathology , Neoplasms, Multiple Primary/blood , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/pathology , Organoplatinum Compounds/adverse effects , Prognosis , Syndrome , Thoracic Wall/pathology , Tomography, X-Ray Computed
17.
JAMA Dermatol ; 153(9): 892-896, 2017 09 01.
Article in English | MEDLINE | ID: mdl-28700773

ABSTRACT

Importance: Persons with human immunodeficiency virus (HIV) have a 2.8-fold higher risk than HIV-uninfected persons of nonmelanoma skin cancer (NMSC), defined as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Individuals with a prior NMSC history are at increased risk for subsequent NMSC, but the magnitude of risk and its relation to HIV disease-related factors, including CD4 count and viral load (VL), are unknown. Objective: To better understand how laboratory markers currently used to evaluate HIV disease progression may be associated with subsequent NMSC risk. Design, Setting, and Participants: This cohort study analyzed 455 HIV-infected and 1945 HIV-uninfected patients, all of them members of the Kaiser Permanente Northern California (KPNC) health care plan, diagnosed with at least 1 NMSC from 1996-2008 to determine risk of subsequent NMSCs in relation to CD4 count and VL. All participants were white, non-Hispanic persons 18 years or older who had had at least 1 NMSC during the 1996-2008 period. Participants entered the cohort at their first NMSC diagnosis and were observed through 2008. Incidence rates were calculated and adjusted hazard ratios were estimated using extended Cox regression models with recent CD4 count and VL analyzed as time-changing covariates. Main Outcomes and Measures: Measured CD4 count, VL, and subsequent NMSC (BCC and SCC). Results: The cohort comprised 455 HIV-infected participants (13 [3%] women) and 1952 HIV-uninfected participants (154 [8%] women). Median duration of observation was 4.6 years, and 16.5% (n = 390) either died (n = 35) or lost KPNC membership status (n = 355) without having a subsequent primary NMSC. Compared with HIV-uninfected persons, HIV-infected individuals were slightly younger (mean age, 52.5 vs 55.5 years), more likely men (97% vs 92%), more likely to have smoked (57% vs 45%), and less likely to be overweight/obese (50% vs 61%). The small observed differences by HIV status in matching characteristics (ie, age and sex) resulted from the restriction of the original cohort to those with at least 1 NMSC. Compared with uninfected individuals, those with HIV infection with a recent biomarker of more severe immune deficiency (CD4 count <200 cells/mL) had a 44% increased risk of subsequent NMSC overall and a 222% increase risk of SCC in particular, suggesting that subsequent SCC risk is associated with immune dysfunction. Conclusions and Relevance: HIV-infected persons compared with HIV-uninfected persons were are at higher risk for subsequent new SCC but not BCC, with a dose-response relationship between risk and lower CD4 counts and higher VLs. Subsequent new primary SCCs had a strong association with lower CD4 and higher VL among HIV-infected persons, suggesting that immune dysfunction might contribute to increased SCC risk. Clinical implications include targeted monitoring for SCC among HIV-infected individuals, particularly those with low CD4 counts or high VLs.


Subject(s)
Carcinoma, Basal Cell/complications , Carcinoma, Squamous Cell/complications , HIV Infections/complications , Neoplasms, Multiple Primary/complications , Skin Neoplasms/complications , Adolescent , Adult , Aged , CD4 Lymphocyte Count , Carcinoma, Basal Cell/blood , Carcinoma, Basal Cell/epidemiology , Carcinoma, Basal Cell/virology , Carcinoma, Squamous Cell/blood , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/virology , Cohort Studies , Female , HIV Infections/blood , HIV Infections/virology , Humans , Male , Middle Aged , Neoplasms, Multiple Primary/blood , Neoplasms, Multiple Primary/epidemiology , Neoplasms, Multiple Primary/virology , Retrospective Studies , Risk Assessment , Skin Neoplasms/blood , Skin Neoplasms/epidemiology , Skin Neoplasms/virology , Viral Load , Young Adult
18.
Urologe A ; 56(9): 1099-1108, 2017 Sep.
Article in German | MEDLINE | ID: mdl-28516190

ABSTRACT

Long-term data demonstrate a higher oncological risk associated with active surveillance (AS) than initially anticipated. In particular, patients with more than two tumor-involved biopsy cores and/or Gleason-7a foci must be regarded as having an increased risk of developing an incurable stage of disease after an initial attempt of AS. For patients with Gleason-7a foci, the 15-year risk of suffering from an incurable tumor stage is reported as high as 60%. Furthermore, life expectancy must be regarded as one of the major risk factors to finally develop symptomatic incurable disease. A discussion has therefore started as to whether a high life expectancy should be regarded as an exclusion criterion against AS. An estimated life expectancy exceeding 15 or 20 years has been proposed for patients suffering from Gleason 7a or 6 foci at initial biopsy, respectively. Furthermore, it must be expected that a number of molecular risk factors will gain importance in the near future for the decision-making process for or against AS.


Subject(s)
Prostatic Neoplasms/therapy , Watchful Waiting , Biomarkers, Tumor/blood , Biopsy, Large-Core Needle , Disease Progression , Follow-Up Studies , Humans , Male , Neoplasm Grading , Neoplasm Staging , Neoplasms, Multiple Primary/blood , Neoplasms, Multiple Primary/pathology , Neoplasms, Multiple Primary/therapy , Prostate/pathology , Prostate-Specific Antigen/blood , Prostatic Neoplasms/blood , Prostatic Neoplasms/mortality , Prostatic Neoplasms/pathology , Risk , Risk Factors , Survival Analysis
19.
Anticancer Res ; 37(5): 2625-2631, 2017 05.
Article in English | MEDLINE | ID: mdl-28476837

ABSTRACT

AIM: The aim of this study was to investigate the prognostic factors associated with extrahepatic metastasis of primary hepatocellular carcinoma (HCC). PATIENTS AND METHODS: We retrospectively analyzed 559 patients with HCC who underwent curative hepatectomy. We divided the patients into no recurrence (NoR), intrahepatic early recurrence (IHER), intrahepatic late recurrence (IHLR), and extrahepatic recurrence (EHR) groups. We compared the non-metastatic group (IHLR and NoR) with the metastatic group (IHER and EHR) and also compared IHER with EHR to determine risk factors for EHR. RESULTS: There were 252, 163, 109, and 35 patients with NoR, IHER, IHLR, and EHR, respectively. For the EHR group, the independent risk factor was vascular invasion. The EHR group had better liver function and worse tumor factors. CONCLUSION: Vascular invasion is predictive of extrahepatic metastasis of HCC.


Subject(s)
Carcinoma, Hepatocellular/pathology , Liver Neoplasms/pathology , Aged , Aspartate Aminotransferases/blood , Carcinoma, Hepatocellular/blood , Carcinoma, Hepatocellular/surgery , Female , Hepatectomy , Humans , Kaplan-Meier Estimate , Liver Neoplasms/blood , Liver Neoplasms/surgery , Logistic Models , Male , Multivariate Analysis , Neoplasm Metastasis , Neoplasm Recurrence, Local , Neoplasms, Multiple Primary/blood , Neoplasms, Multiple Primary/pathology , Neoplasms, Multiple Primary/surgery , Prognosis , Risk Factors , Serum Albumin/analysis
20.
Anticancer Res ; 37(2): 865-870, 2017 02.
Article in English | MEDLINE | ID: mdl-28179344

ABSTRACT

BACKGROUND: Colorectal cancer (CRC) with peritoneal carcinomatosis (PC) has the worst prognosis among all types of metastases, but is difficult to diagnose. This study investigated whether preoperative serum carbohydrate antigen (CA) 19-9 level can predict synchronous PC in patients with primary CRC. PATIENTS AND METHODS: The cases of 395 CRC patients who underwent primary lesion resection were retrospectively reviewed. Risk factors were evaluated by uni- and multivariate analyses from clinicopathological data. RESULTS: In the univariate analysis, tumor invasion (p<0.001), lymph node and hematogenous metastases (p=0.037 and p<0.001, respectively), and elevated preoperative serum CA19-9 level (p<0.001) were associated with synchronous PC, and multiple regression analysis revealed that an elevated preoperative serum CA19-9 level was an independent risk factor for PC (odds ratio=5.03, 95% confidence interval=1.29-19.60, p=0.020). CONCLUSION: Elevated preoperative serum CA 19-9 level may be useful in predicting synchronous PC in patients with CRC.


Subject(s)
CA-19-9 Antigen/blood , Colorectal Neoplasms/blood , Neoplasms, Multiple Primary/blood , Peritoneal Neoplasms/blood , Adult , Aged , Aged, 80 and over , Colorectal Neoplasms/pathology , Female , Humans , Male , Middle Aged , Multivariate Analysis , Neoplasms, Multiple Primary/diagnosis , Peritoneal Neoplasms/diagnosis , Peritoneal Neoplasms/secondary , Preoperative Period , Prognosis , Regression Analysis , Retrospective Studies , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL